Corvus Pharmaceuticals
CRVS
35 hedge funds and large institutions have $68.9M invested in Corvus Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 12 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
5.11% less ownership
Funds ownership: 83% → 77.89% (-5.1%)
22% less funds holding
Funds holding: 45 → 35 (-10)
29% less capital inflows, than outflows
Capital inflows: $8.17M | Capital outflows: $11.5M
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.68M |
| 2 |
BVF Inc
San Francisco,
California
|
+$1.14M |
| 3 |
OrbiMed
New York
|
+$847K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$363K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$6.27M |
| 2 |
PCM
Puissance Capital Management
New York
|
-$1.04M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$695K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$635K |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$624K |
CRVS Hedge Fund Activity: Q3 2019 in Review
35 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2019, worth a combined $68.9M — down 24% from $91M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of CRVS and 3 opened new positions — a net loss of 9 holders — while 11 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, adding an estimated $3.68M. The largest seller was Novo Holdings A/S, cutting an estimated $6.27M.
- 35 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2019, down from 45 in Q2 2019.
- Funds reported $68.9M of Corvus Pharmaceuticals stock for Q3 2019, down 24% quarter-over-quarter.
- 3 funds opened new Corvus Pharmaceuticals positions in Q3 2019 and 12 closed out, a net change of -9 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2019 was Millennium Management, an estimated $3.68M added.
- The largest Corvus Pharmaceuticals seller in Q3 2019 was Novo Holdings A/S, an estimated $6.27M sold.
Based on aggregated 13F filings for Q3 2019.